These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 22447658)

  • 1. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.
    Luo J; Liu X
    Protein Cell; 2012 Mar; 3(3):182-97. PubMed ID: 22447658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors.
    Pezuk JA; Valera ET; Brassesco MS
    Curr Drug Targets; 2016; 17(14):1661-1672. PubMed ID: 26302797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.
    Liu XS; Song B; Elzey BD; Ratliff TL; Konieczny SF; Cheng L; Ahmad N; Liu X
    J Biol Chem; 2011 Oct; 286(41):35795-35800. PubMed ID: 21890624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.
    Petronczki M; Lénárt P; Peters JM
    Dev Cell; 2008 May; 14(5):646-59. PubMed ID: 18477449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development.
    Takaki T; Trenz K; Costanzo V; Petronczki M
    Curr Opin Cell Biol; 2008 Dec; 20(6):650-60. PubMed ID: 19000759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase (Plk) 1 as a target for prostate cancer management.
    Reagan-Shaw S; Ahmad N
    IUBMB Life; 2005 Oct; 57(10):677-82. PubMed ID: 16223707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polo-like Kinase 1 as a Target for Anti-tumor Therapy].
    Procházková I; Vojtěšek B
    Klin Onkol; 2015; 28 Suppl 2():2S32-9. PubMed ID: 26374156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shared and separate functions of polo-like kinases and aurora kinases in cancer.
    Lens SM; Voest EE; Medema RH
    Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation.
    Lasek AL; McPherson BM; Trueman NG; Burkard ME
    PLoS One; 2016; 11(2):e0150225. PubMed ID: 26919439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
    Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC; Schuler M
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies.
    Wachowicz P; Fernández-Miranda G; Marugán C; Escobar B; de Cárcer G
    Bioessays; 2016 Jul; 38 Suppl 1():S96-S106. PubMed ID: 27417127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.
    Fink J; Sanders K; Rippl A; Finkernagel S; Beckers TL; Schmidt M
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3189-97. PubMed ID: 18089713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.
    Santamaria A; Neef R; Eberspächer U; Eis K; Husemann M; Mumberg D; Prechtl S; Schulze V; Siemeister G; Wortmann L; Barr FA; Nigg EA
    Mol Biol Cell; 2007 Oct; 18(10):4024-36. PubMed ID: 17671160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinases inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells.
    Burkard ME; Randall CL; Larochelle S; Zhang C; Shokat KM; Fisher RP; Jallepalli PV
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4383-8. PubMed ID: 17360533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
    Ergul M; Bakar-Ates F
    Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illumination of mitotic orchestra during cell division: a Polo view.
    Yuan K; Huang Y; Yao X
    Cell Signal; 2011 Jan; 23(1):1-5. PubMed ID: 20633640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?
    Archambault V; Carmena M
    Cell Cycle; 2012 Apr; 11(8):1490-5. PubMed ID: 22433949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.